FGF23 and the parathyroid

Advances in Experimental Medicine and Biology

Volumn 728, Issue , 2012, Pages 92-99

  Silver, Justin ^a   Naveh Many, Tally ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIDIOL 1 MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PARATHYROID HORMONE; FIBROBLAST GROWTH FACTOR;

ARTICLE; CHRONIC KIDNEY DISEASE; DOWN REGULATION; ENZYME ACTIVATION; GENE; HORMONE PROTEIN COMPLEX; HORMONE RESISTANCE; HORMONE SYNTHESIS; HUMAN; NONHUMAN; PARATHYROID CELL; PARATHYROID FUNCTION; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE GENE; PARATHYROID HORMONE RELEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; ANIMAL; CYTOLOGY; GENE EXPRESSION REGULATION; KIDNEY DISEASE; METABOLISM; PATHOLOGY; REVIEW;

RATTUS;

ANIMALS; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; PARATHYROID GLANDS;

EID: 84859530375     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-0887-1_6     Document Type: Article

References (38)

1. White KE, Evans WE, ORiordan JLH et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26(3):345-348
2. Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad SciUSA2001;98(ll):6500-6505
3. Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19(3):429-435
4. Kurosu H, Ogawa Y, Miyoshi M et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281(10):6120-6123
5. Araya K, Fukumoto S, Backenroth R et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005;90(10):5523-5527
6. Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006; 15(4):437-441
7. Farrow EG, Davis SI, Summers LJ et al. Initial FGF23-Mediated Signaling Occurs in the Distal Convoluted Tubule. J Am Soc Nephrol 2009; 20(5):955-960
8. Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect ofklotho gene expression. Circulation 2004; 109(14):1776-1782
9. Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444(7120):770-774
10. White KE, Jonsson KB, Carn G et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 2001; 86(2):497-500
11. Shimada T, Urakawa I, Yamazaki Y et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type Ila. Biochem Biophys Res Commun 2004; 314(2):409-414
12. Bai XY, Miao D, Goltzman D et al. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 2003; 278(11):9843-9849
13. Bai X, Miao D, Li J et al. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinol 2004; 145(11):5269-5279
14. Larsson T, Marsell R, Schipani E et al. Transgenic mice expressing Fibroblast Growth Factor 23 under the control of the {alpha}1(I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinol 2004; 145:3087-3094
15. Ben Dov IZ, Galitzer H, Lavi-Moshayoff V et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007; 117(12):4003-4008
16. Goetz R, Beenken A, Ibrahimi OA et al. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action ofFGF19 Subfamily Members. Mol Cell Biol 2007; 27(9):3417-3428
17. YamashitaT, Konishi M, Miyake A. Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem 2002; 277(31):28265-28270
18. Krajisnik T, Bjorklund P, Marsell R et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007; 195(1):125-131
19. Lavi-MoshayoffV, Silver J, Naveh-Many T. Human PTH gene regulation in vivo using transgenic mice. Am J Physiol Renal Physiol 2009; 297(3):F713-F719
20. Yamazaki Y, Tamada T, Kasai N et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features ofFGF23. J Bone Miner Res 2008; 23(9):1509-1518
21. Imanishi Y, Inaba M, Nakatsuka K et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65(5):1943-1946
22. Isakova T, Gutierrez O, Shah A et al. Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 2008; 19(3):615-623
23. Westerberg PA, Linde T, Wikstrom B. Regulation of fibroblast growth factor-23 in chronic kidney disease. Nephrol Dial Transplant 2007; 22(11):3202-3207
24. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007; 71(1):31-38
25. Silver J, Kilav R, Naveh-Many T. Mechanisms of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2002; 283(3):F367-F376
26. Meir T, Levi R, Lieben L et al. Deletion ofthe vitamin D receptor specifically in the parathyroid demonstrates a limited role for the VDR in parathyroid physiology. Am J Physiol Renal Physiol 2009
27. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16(7):2205-2215
28. Fliser D, Kollerits B, Neyer Uet al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) Study. J Am Soc Nephrol 2007; 18(9):2600-2608
29. Nakanishi S, Kazama JJ, Nii-Kono T et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int2005; 67(3):1171-1178
30. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359(6):584-592
31. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 2010; 77(3):211-218
32. Komaba H, Goto S, Fujii H et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 2009
33. KomabaH, FukagawaM. FGF23-parathyroidinteraction: implications in chronickidney disease. Kidney Int2009
34. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18(10):2683-2688
35. Brown WW, Juppner H, Langman CB et al. Hypophosphatemia with elevations in serum FGF23 in a child with Jansens Metaphyseal Chondrodysplasia (FGF23 in Jansens Syndrome). J Clin Endocrinol Metab 2008
36. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289(5):F1088-F1095
37. Canalejo R, Canalejo A, Martinez-Moreno JM et al. FGF23 fails to inhibit uremic parathyroid glands. J AmSoc Nephrol 2010; 21(7):1125-1135
38. Lavi-MoshayoffV, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. AM J Physio Renal Physiol 2010; 299(4):F882-9